May 22, 2017 / 6:20 AM / 3 months ago

BRIEF-Poxel reports positive data on Imeglimin's phase 1

May 22 (Reuters) - POXEL SA:

* PHASE 1 DATA IN JAPANESE SUBJECTS DEMONSTRATED IMEGLIMIN WAS SAFE, WELL TOLERATED AND EXHIBITED A SIMILAR PHARMACOKINETIC PROFILE TO WHAT WAS OBSERVED IN CAUCASIAN SUBJECTS

* MECHANISTIC DATA SHOWS IMEGLIMIN'S BENEFIT ON BETA CELL PROTECTION AND DETAILS ITS UNIQUE INSULIN SECRETION PATHWAY IN RESPONSE TO GLUCOSE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below